The human papillomavirus (HPV) is an important causal agent of premalignant cervical epithelial changes and cervical cancers. These cancers account for ∼5% of all cancers globally and kill more than a quarter million women annually. HPV infections also associate with certain anogenital and oropharyngeal cancers. Events leading to the development of HPV vaccines to prevent associated cancers are described, with a further discussion of goals that must be met to achieve full virus eradication.
Get full access to this article
View all access options for this article.
References
1.
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 2007; 356:1915–1927.
2.
ArnoldAW, and HofbauerGF. Human papillomavirus and squamous cell cancer of the skin—epidermodysplasia verruciformis-associated human papillomavirus revisited. Curr Probl Dermatol, 2012; 43:49–56.
3.
BaayMF, DukJM, GroenierKH, et al.Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies. Cancer Immunol Immunother, 1997; 44:211–215.
4.
BarbosaMS, and SchlegelR. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene, 1989; 4:1529–1532.
5.
BasemanJG, and KoutskyLA. The epidemiology of human papillomavirus infections. J Clin Virol, 2005; 32Suppl 1:S16–S24.
6.
BellJA, SundbergJP, GhimSJ, et al.A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology, 1994; 62:194–198.
7.
BernardHU, BurkRD, ChenZ, et al.Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology, 2010; 401:70–79.
8.
BishopB, DasguptaJ, KleinM, et al.Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem, 2007; 282:31803–31811.
9.
BoschFX, BurchellAN, SchiffmanM, et al.Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 2008; 26Suppl 10:K1–K16.
10.
BoshartM, GissmannL, IkenbergH, et al.A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J, 1984; 3:1151–1157.
11.
BreitburdF, KirnbauerR, HubbertNL, et al.Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol, 1995; 69:3959–3963.
12.
BrothertonJM, WinchKL, BicknellL, et al.HPV vaccine coverage is increasing in Australia. Med J Aust, 2017; 206:262.
13.
BrowneHM, ChurcherMJ, StanleyMA, et al.Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant. J Gen Virol, 1988; 69 (Pt 6):1263–1273.
14.
BruniL, DiazM, Barrionuevo-RosasL, et al.Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health, 2016; 4:e453–e463.
15.
CastellsagueX. Natural history and epidemiology of HPV infection and cervical cancer. Gynaecol Oncol, 2008; 110:S4–S7.
16.
ChengG, IcenogleJP, KirnbauerR, et al.Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis, 1995; 172:1584–1587.
17.
ChowLT, BrokerTR, and SteinbergBM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS, 2010; 118:422–449.
18.
ChristensenND, DillnerJ, EklundC, et al.Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology, 1996; 223:174–184.
19.
de MartelC, PlummerM, VignatJ, et al.Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer, 2017; 141:664–670.
20.
de QuadrosCA. Is global measles eradication feasible?. Curr Top Microbiol Immunol, 2006; 304:153–163.
21.
De VincenzoR, RicciC, ConteC, et al.HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol, 2013; 130:642–651.
22.
DillnerJ. The serological response to papillomaviruses. Semin Cancer Biol, 1999; 9:423–430.
23.
DorjiT, TshomoU, PhuntshoS, et al.Introduction of a National HPV vaccination program into Bhutan. Vaccine, 2015; 33:3726–3730.
24.
DroletM, BenardE, BoilyMC, et al.Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis, 2015; 15:565–580.
25.
DurstM, GissmannL, IkenbergH, et al.A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A, 1983; 80:3812–3815.
26.
EmenyRT, WheelerCM, JansenKU, et al.Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol, 2002; 76:7832–7842.
27.
FergusonM, WilkinsonDE, HeathA, et al.The first international standard for antibodies to HPV 16. Vaccine, 2011; 29:6520–6526.
28.
GallagherKE, HowardN, KabakamaS, et al.Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. PLoS One, 2017; 12:e0177773.
29.
GanzenmuellerT, YakushkoY, KlubaJ, et al.Next-generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int J Cancer, 2012; 131:E1173–E1179.
30.
GertigDM, BrothertonJM, BuddAC, et al.Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med, 2013; 11:227.
31.
GiroglouT, SappM, LaneC, et al.Immunological analyses of human papillomavirus capsids. Vaccine, 2001; 19:1783–1793.
32.
GissmannL, and HausenHZ. Human papilloma virus DNA: physical mapping and genetic heterogeneity. Proc Natl Acad Sci U S A, 1976; 73:1310–1313.
33.
HaffarO, GarriguesJ, TravisB, et al.Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol, 1990; 64:2653–2659.
34.
HemminkiK, and ChenB. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev, 2006; 15:1413–1414.
35.
HofmannKJ, CookJC, JoyceJG, et al.Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology, 1995; 209:506–518.
36.
JaguS, KwakK, KaranamB, et al.Optimization of multimeric human papillomavirus L2 vaccines. PLoS One, 2013; 8:e55538.
37.
JarrettWF, O'NeilBW, GaukrogerJM, et al.Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec, 1990; 126:449–452.
38.
JiangRT, WangJW, PengS, et al.Spontaneous and vaccine-induced clearance of mus musculus papillomavirus 1 infection. J Virol, 2017; 91:e00699–17.
39.
KirnbauerR, BooyF, ChengN, et al.Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A, 1992; 89:12180–12184.
40.
KjellbergL, HallmansG, AhrenAM, et al.Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer, 2000; 82:1332–1338.
41.
KoutskyL. The epidemiology behind the HPV vaccine discovery. Ann Epidemiol, 2009; 19:239–244.
42.
KreimerAR, StruyfF, Del Rosario-RaymundoMR, et al.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol, 2015; 16:775–786.
43.
LeoPJ, MadeleineMM, WangS, et al.Defining the genetic susceptibility to cervical neoplasia—a genome-wide association study. PLoS Genet, 2017; 13:e1006866.
44.
LinYL, BorensteinLA, SelvakumarR, et al.Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology, 1992; 187:612–619.
45.
MachH, VolkinDB, TroutmanRD, et al.Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci, 2006; 95:2195–2206.
46.
MarianiL, PretiM, CristoforoniP, et al.Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynaecol Obstet, 2017; 136:258–265.
47.
MarkowitzLE, DunneEF, SaraiyaM, et al.Quadrivalent Human Papillomavirus Vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2007; 56:1–24.
48.
MüllerM, GausepohlH, De MartynoffG, et al.Identification of seroreactive regions of the human papillomavirus type 16 proteins E4, E6, E7 and L1. J Gen Virol, 1990; 71:2709–2717.
49.
MunozN, and BoschFX. Epidemiology of cervical cancer. IARC Sci Publ, 1989; 119:9–39.
50.
PeñaLD, and LaiminsLA. Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression. J Virol, 2001; 75:10005–10013.
51.
PetroskyE, BocchiniJAJr., HaririS, et al.Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep, 2015; 64:300–304.
52.
PyeonD, PearceSM, LankSM, et al.Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog, 2009; 5:e1000318.
53.
RichardsonH, KelsallG, TellierP, et al.The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev, 2003; 12:485–490.
54.
RobertsC, GreenT, HessE, et al.Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Human Vaccin Immunother, 2014; 10:2168–2174.
55.
RoseRC, BonnezW, Da RinC, et al.Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol, 1994; 75:2445–2449.
56.
SchadlichL, SengerT, GerlachB, et al.Analysis of modified HPV 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol, 2009; 83:7690–7705.
57.
SchillerJT, CastellsagueX, and GarlandSM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine, 2012; 30Suppl 5:F123–F138.
58.
ScottoJOSE, and Bailar JCIII. Rigoni-Stern and medical statistics. A nineteenth-century approach to cancer research. J Hist Med Allied Sci, 1969; 24:65–75.
59.
SehrP, MullerM, HopflR, et al.HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods, 2002; 106:61–70.
60.
SmithEM, ParkerMA, RubensteinLM, et al.Evidence for vertical transmission of HPV from mothers to infants. Infect Dis Obstet Gynecol, 2010; 2010:326369.
61.
SmithJF, KowalskiR, EsserMT, et al.Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum vaccin, 2008; 4:134–142.
62.
StanleyMA, and SterlingJC. Host responses to infection with human papillomavirus. Curr Probl Dermatol, 2014; 45:58–74.
63.
van BogaertL. Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?. Ann Med Health Sci Res, 2013; 3:306–312.
64.
Van DoorslaerK. Evolution of the papillomaviridae. Virology, 2013; 445:11–20.
65.
Van DoorslaerK, LiZ, XirasagarS, et al.The Papillomavirus Episteme: a major update to the papillomavirus sequence database. Nucleic Acids Res, 2017; 45:D499–D506.
ViscidiRP, KotloffKL, ClaymanB, et al.Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol, 1997; 4:122–126.
68.
WangJW, JaguS, WangC, et al.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One, 2014; 9:e101576.
69.
WheelerCM. The natural history of cervical human papillomavirus infections and cervical cancer: gaps in knowledge and future horizons. Obstet Gynecol Clin North Am, 2013; 40:165–176.
70.
YangA, FarmerE, LinJ, et al.The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res, 2017; 231:148–165.
71.
ZhaoQ, ModisY, HighK, et al.Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J, 2012; 9:52.
72.
ZhouJ, LiuWJ, PengSW, et al.Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol, 1999; 73:4972–4982.
73.
ZhouJ, StenzelDJ, SunXY, et al.Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol, 1993; 74 (Pt 4):763–768.
74.
ZhouJ, SunXY, and FrazerIH. Glycosylation of human papillomavirus type 16 L1 protein. Virology, 1993; 194:210–218.
75.
ZhouJ, SunXY, StenzelDJ, et al.Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991; 185:251–257.
